Safety and Biomarker Study of EPI-589 in Participants With Amyotrophic Lateral Sclerosis (ALS)

Inclusion Criteria

• •Diagnosis of possible, probable, laboratory supported probable, or definite ALS by E1 Escorial Criteria
• •Forced vital capacity (FVC) ≥ 70% of predicted
• •Weakness onset within 3 years
• •Agreement to use contraception if within reproductive years
• •Willingness and ability to comply with study procedures
• •Stable regimen of dietary supplements and /or riluzole for at least 30 days prior to enrollment
• •Abstention from use of other investigative or non-approved drugs
• •Participants must be able to swallow 0.375 \* 0.700 inch tablets